. 2019 Sep 26;49(11):e13168. doi: 10.1111/eci.13168

Table 2.

GDF‐15 levels and laboratory parameters according to tertiles in unselected treatment‐naïve cancer patients (n = 555)

	1. tertile	2. tertile	3. tertile	P‐value
GDF‐15, ng/L (IQR)	170 (146‐205)	338 (281‐387)	635 (534‐828)	‐
NT‐proBNP, pg/mL (IQR)	76 (44‐126)^a, ^b	139 (72‐255)^a, ^§	231 (116‐729)^§, ^b	<.001
hsTnT, ng/L (IQR)	3 (3‐5)^a, ^b	7 (3‐11)^a, ^§	9 (5‐16)^§, ^b	<.001
GFR, mL/min/1.73 m² (IQR)	80.2 (70.4‐88.6)^a, ^b	73.6 (64.0‐83.0)^a, ^§	66.2 (54.7‐81.1)^§, ^b	<.001
BUN, mg/dL (IQR)	13 (11‐16)^a, ^b	16 (12‐19)^a, ^§	18 (14‐23)^§, ^b	<.001
Bilirubin, mg/dL (IQR)	0.6 (0.4‐0.7)^b	0.6 (0.4‐0.8)^§	0.6 (0.5‐0.9)^§, ^b	.029
GGT, U/L (IQR)	26 (17‐42)^a, ^b	33 (24‐49)^a, ^§	52 (26‐107)^§, ^b	<.001
AST (GOT), U/L (IQR)	21 (18‐28)^a, ^b	24 (20‐30)^a, ^§	28 (21‐40)^§, ^b	<.001
ALT (GPT), U/L (IQR)	21 (16‐29)	23 (17‐32)	22 (15‐36)	.323
BChE, kU/L (IQR)	7.7 (6.8‐9.1)^b	7.6 (6.4‐8.6)^§	6.3 (4.9‐7.6)^§, ^b	<.001
Albumin, g/L (IQR)	44.2 (42.5‐46.5)^a, ^b	43.3 (40.5‐45.4)^a, ^§	40.6 (37.2‐43.2)^§, ^b	<.001

Fonts in bold indicate statistical significance (P < .05).

^{^a}

tertile1 vs tertile2.

^{^§}

tertile2 vs tertile3.

^{^b}

tertile1 vs tertile3.